Nemus Bioscience has entered an agreement with Albany Molecular Research (AMRI) for the development and manufacture of Nemus’ cannabinoid-based API. AMRI will leverage its process chemistry expertise in the synthesis and formulation of Nemus’ prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, which is in development for the treatment of glaucoma.

“Advancing our lead therapeutic candidates into the API manufacturing stage is a major milestone for our company and is pivotal for initiating human studies,” commented Brian Murphy, M.D., chief executive officer of Nemus. “Cannabinoid-based therapies have the potential to revolutionize glaucoma therapy by not only lowering intraocular pressure, but by exerting a direct neuroprotective effect on the cells of the optic nerve, thereby preserving vision.” 

“AMRI looks forward to working with Nemus to bring this new class of cannabinoid-based therapies through the developmental process,” said Christopher Conway, senior vice president of Discovery and Development Services at AMRI. “AMRI will focus on manufacturing synthetic versions of Nemus’ proprietary prodrug of THC at our U.S. Drug Enforcement Administration (DEA) approved facilities.”